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Problem: Maternal methylmercury (MeHg) exposure may be associated with immune 
response during pregnancy.
Method of study:	 In	 the	 high	 fish-	eating	 Seychelles	 Child	 Development	 Study	
Nutrition Cohort 2, we examined the association between maternal MeHg, polyun-
saturated	fatty	acids	(PUFA),	and	immune	markers	(Th1:Th2;	TNF-	α,	IL-	1β,	IFN-	γ,	IL-	2,	
IL-	4,	IL-	5,	IL-	10,	MCP-	1,	TARC,	sFlt-	1,	VEGF-D,	CRP	and	IL-	6)	at	28	weeks’	gestation.	
Linear regression examined associations between MeHg exposure and immune 
markers	with	and	without	adjustment	for	PUFA.
Results: In all models, as MeHg concentrations increased, the Th1:Th2 ratio, total Th1 
and	individual	Th1	(IL-	1β,	IL-	2,	TNF-	α) concentrations decreased. MeHg was not as-
sociated	with	total	Th2	cytokines	but	was	associated	with	a	decrease	in	IL-	4	and	IL-	
10.	MeHg	was	positively	associated	with	TARC	and	VEGF-D	and	negatively	associated	
with	CRP.	There	was	a	significant	interaction	between	MeHg	and	the	n-	6:n-	3	ratio,	
with	MeHg	associated	with	a	larger	decrease	in	Th1:Th2	at	higher	n-	6:n-	3	PUFA	ra-
tios.	The	n-	3	PUFA	were	associated	with	lower	CRP,	IL-	4	and	higher	IFN-	γ.	The	n-	6	
PUFA	were	associated	with	higher	IL-	1β,	IL-	2,	TNF-	α,	IL-	4,	IL-	10,	CRP	and	IL-	6.
Conclusion: Maternal MeHg was associated with markers of immune function at 
28	weeks’	gestation.	A	significant	interaction	between	MeHg	and	the	n-	6:n-	3	ratio	
on	the	Th1:Th2	ratio	suggests	that	the	n-	3	PUFA	may	mitigate	any	immunosuppres-
sive	associations	of	MeHg.	The	n-	3	and	n-	6	PUFA	were	associated	with	suppressive	
and stimulatory immune responses, respectively. Overall, the associations were of 
small magnitude, and further research is required to determine the clinical 
significance.
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1  | INTRODUC TION
The	 immune	 system	 during	 pregnancy	 is	 defined	 by	 maternal-	
placental tolerance facilitated via immune cell activation and cyto-
kine release.1,2	 In	 normal	 pregnancy,	 the	 balance	 of	 T-	helper	 (Th)	
1	 (cell-	mediated	 immunity)	 to	Th2	 (humoral	 immunity)	 cell	 activity	
is characterized by a more pronounced Th1 proinflammatory re-
sponse in the first trimester, required for successful implantation.2,3 
Thereafter,	 there	 is	 a	 shift	 towards	 greater	 Th2	 anti-inflammatory	
cell activity and downregulation of Th1 cell activity in the second 
and third trimesters to allow maternal tolerance to the developing 
foetus.4-6 The immune response returns to a Th1 proinflammatory 
phase towards the end of the third trimester to initiate the labour 
process.7 It has been suggested that a lower index of Th1:Th2 im-
mune response in the second trimester is supportive for successful 
physiologic pregnancy.2,8 In the second trimester, Th2 cells secrete 
predominantly	 anti-inflammatory	 cytokines	 including	 interleukin	
(IL)-	4,	IL-	5	and	IL-	10	which,	in	combination	with	a	reduction	in	inflam-
matory	Th1	cytokines	IL-	1β,	IL-	2	and	interferon-	gamma	(IFN-	γ), have 
been associated with healthy term pregnancy.9,10 Therefore, specific 
balance	 between	maternal	 proinflammatory	 and	 anti-inflammatory	
cytokines throughout pregnancy is believed to be critical for the suc-
cess of a pregnancy and favourable birth outcomes.11 The normal 
variation, however, in the magnitude of these immunologic changes 
during pregnancy has not been fully defined.
Pregnant	women	are	encouraged	to	consume	fish	because	fish	are	
rich	in	nutrients	including	long-	chain	n-	3	polyunsaturated	fatty	acids	
(PUFA),	which	are	important	for	normal	brain	development.12 However, 
fish consumption advisories have been issued based on the limited epi-
demiological evidence that there might be neurotoxicity from the small 
amounts of naturally acquired methylmercury (MeHg) which is found 
in all fish. MeHg exposure has been associated with markers of im-
mune response13 albeit its association with immune function in preg-
nancy is not known. Cytokine dysregulation, however, as a result of 
MeHg exposure has been reported in animal models.14 Evidence from 
in	vitro	and	murine	models	suggests	that	MeHg	reduces	T-	and	B-	cell	
responses, and this immunosuppressive response has been demon-
strated in vivo and is associated with changes in immune function.15,16 
Most work in this area has focused on inorganic Hg species. Treatment 
of	human	peripheral	blood	mononuclear	cells	(PBMCs)	with	mercury	
chloride (HgCl2) was found to significantly increase the release of the 
proinflammatory	cytokines	tumour	necrosis	factor	(TNF)-	α,	IL-	1β and 
IL-	6	 in	 a	 dose-	dependent	manner17-19 and to reduce the concentra-
tion	of	the	anti-inflammatory	markers	IL-	1Ra	and	IL-	10.18 In contrast, 
MeHg exposure is thought to produce an initial immunosuppressive 
response,	characterized	by	reduced	B-	and	T-	cell	numbers	followed	by	
a delayed Th1 response, which may persist long after exposure.13,16 
One	observational	study	of	high	fish-	eating	mothers	found	an	elevated	
IgG response apparent with MeHg exposure and may be indicative of 
an autoimmune type response.20 No other study, to our knowledge, 
has investigated MeHg exposure on maternal immune response.
The	 n-	3	 PUFA	 have	 been	 suggested	 to	 protect	 against	 oxidative	
insult and to have beneficial effects on immune function and 
inflammation in pregnancy.21-23	 Long-	chain	 n-	3	 PUFA,	 together	
with	 long-	chain	n-	6	PUFA	(eg	arachidonic	acid	 [AA]),	have	 impor-
tant roles in inflammation by acting as precursors for eicosanoid 
and docosanoid signalling molecules. These signalling molecules, 
including the proresolvins and lipoxins, have roles not only in in-
flammation but also in inducing active resolution of inflammation 
and thereby having a protective function against uncontrolled in-
flammation.24,25 Inflammation is nonspecific, and although regu-
lated by cytokine expression, it does not always follow the Th1:Th2 
hypothesis.26	 Therefore,	 the	 beneficial	 effects	 of	 n-	3	 PUFA	may	
not be reflected through favouring either a Th1 or Th2 response.27 
However,	the	anti-inflammatory	actions	of	n-	3	PUFA	are	widely	ac-
knowledged and have largely been reported to involve the suppres-
sion of proinflammatory cytokines and the enhanced production 
of	 more	 anti-inflammatory	 cytokines,	 possibly	 at	 the	 eicosanoid	
rather	 than	 Th-	cell	 level.28-31	 The	 n-	6	 PUFA-	derived	 eicosanoids	
are generally proinflammatory,32	 while	 the	 anti-inflammatory	 ef-
fects	of	n-	3	PUFA	 (suppression	of	Th1	and	enhancement	of	anti-
inflammatory Th2 cytokines) are widely reported.28 Therefore, a 
higher	concentration	of	n-	3	PUFA	along	with	a	lower	n-	6:n-	3	ratio	is	
suggested	to	be	important	in	regulating	inflammation.	Previously	in	
the Seychelles Child Development Study (SCDS) Nutrition Cohort 
2	(NC2),	we	reported	that	MeHg-	induced	inflammation	might	de-
pend	on	the	physiologic	balance	of	n-	6	to	n-	3	PUFA.33 Therefore, 
we examined the associations between maternal MeHg exposure, 
PUFA	 and	maternal	 blood	markers	 of	 inflammation	 at	 28	weeks’	
gestation in the NC2 to better understand the risk/benefit of fish 
consumption during pregnancy.
2  | METHODS
2.1 | Study population
Participants	 for	 this	 study	 are	 part	 of	 the	 SCDS	Nutrition	Cohort	
2 (NC2) which has been described in detail elsewhere.33 In brief, 
between	2008	and	2011,	a	large	mother-	child	cohort	(n	=	1518	eli-
gible mothers) was recruited. Mothers were enrolled during their 
first antenatal visit (from 14 week of gestation) at eight health cen-
tres across the island of Mahé. Inclusion criteria for NC2 included 
being	native	Seychellois,	being	=>16	years	of	age,	and	having	a	sin-
gleton pregnancy, with no obvious health concerns. The study was 
reviewed and approved by the Seychelles Ethics Board and the 
Research Subjects Review Board at the University of Rochester.
2.2 | Blood collection
At	28	weeks	of	gestation,	nonfasting	maternal	blood	samples	were	
collected by antecubital venepuncture into evacuated serum and 
EDTA	 tubes	 and	 were	 immediately	 processed	 by	 centrifuging	 at	
700 g	for	15	minutes.	All	samples	were	stored	at	−80°C	and	main-
tained at this temperature throughout their shipment to Ulster 
University for storage and analysis.
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2.3 | MeHg exposure
Maternal	 whole-	blood	 samples	 were	 shipped	 to	 the	 University	
of	 Rochester	 for	 total	 Hg	 (THg)	 analysis	 using	 a	 PSA	Millennium	
Merlin	 System	 (PS	 Analytical,	 Kent,	 UK).	 Our	 limit	 of	 detection	
for THg in blood is ~0.01 ng/mL, depending on sample volume34. 
Standard	 Reference	 Materials	 (SRM	 966	 Toxic	 Metals	 in	 Bovine	
Blood	 and	 Seronorm	 201605)	 were	 purchased	 from	 the	 National	
Institute of Standards and Technology (Gaithersburg, MD) and SERO 
(Billingstad,	Norway),	 respectively.	We	did	not	speciate	Hg.	All	Hg	
results presented as MeHg are total Hg (THg) based on the assump-
tion that ~80% of THg in whole blood is MeHg within the Seychelles 
population.35,36
2.4 | Inflammatory markers
Serum samples were analysed at Ulster for a panel of inflammatory 
markers by Meso Scale Discovery (MSD) multiplex assay (Meso Scale 
Diagnostics, LLC.). These assays yield greater sensitivity and larger dy-
namic range and require less sample volume than traditional methods 
for immunoassays.37	 In	preliminary	analysis,	we	screened	50	mater-
nal	samples	using	a	V-	PLEX	human	biomarker	40-	Plex	MSD	panel	of	
immune markers. Based on significant associations in our preliminary 
analysis, reported MeHg associations in the literature, and reported 
n-	3	 long-	chain	 polyunsaturated	 fatty	 acid	 status,	 we	 determined	 a	
panel of inflammatory markers to be assessed in maternal serum sam-
ples.20	Cytokines	that	were	measured	for	cell-	mediated	inflammatory	
reactions	(Th1)	included	IL-	1β,	IL-	2,	IFN-	γ	and	TNF-	α. The cytokines as-
sociated	with	Th2-	cell	activity	included	IL-	4,	IL-	5	and	IL-	10.	In	addition,	
we	measured	IL-	6	which	plays	a	dual	role	in	Th1:Th2	differentiation38 
and is largely a proinflammatory cytokine which has been shown to be 
stimulated in vitro following MeHg exposure.39,40	We	measured	two	
pregnancy-	associated	 chemokines,	 monocyte	 chemotactic	 protein-
	1	 (MCP-	1)	and	 thymus-	and	activation-regulated	chemokine	 (TARC)	
and two angiogenesis markers noted to be important for maintenance 
of	 placental	 vascular	 development	 and	 blood	 flow,	 soluble	 fms-	like	
tyrosine	 kinase-	1	 (sFlt-	1)	 and	 a	member	 of	 the	 vascular	 endothelial	
growth	factor	(VEGF)		family,	VEGF-	D.	Flow	cytometry	analysis	was	
not possible given the retrospective nature of this study, and there-
fore, the sum of cytokines concentrations (pg/mL) was used to reflect 
the	Th1:Th2	ratio	as	follows:	Th1-	type	cell	activity:	IL-	1β,	 IL-	2,	IFN-	γ 
and	TNF-	α;	and	Th2-	cell	activity:	IL-	4,	IL-	5	and	IL-	10.	We	analysed	the	
remaining	markers	 individually:	 CRP,	 IL-	6,	MCP-	1,	 TARC,	 sFlt-	1	 and	
VEGF-	D.	CRP	(mg/L)	was	measured	by	Ultra-	Sensitive	diagnostic	kit	
using	the	iLab	650	Clinical	Chemistry	Analyzer.
2.5 | PUFA status
Maternal	serum	samples	were	used	to	determine	total	PUFA	analy-
sis at Ulster University, using a method adapted from that of Folch 
et al41 Fatty acid methyl esters were detected and quantified by using 
the	gold-	standard	technique	of	gas	chromatography-	mass	spectrom-
etry	(7890A-	5975C;	Agilent)	using	heptadecanoic	acid	(C17:0)	as	the	
internal standard, as previously described.42	 All	 analytic	 standards	
were	of	=>99%	purity	and	purchased	from	Sigma-	Aldrich.	Total	serum	
PUFA	status	was	chosen	as	a	biomarker	of	PUFA	concentrations	rep-
resenting the triacylglycerol fraction, to which the majority of circulat-
ing	PUFA	are	bound	during	pregnancy.43	We	measured	the	individual	
PUFA	(linoleic	acid	[LA],	arachidonic	acid	[AA],	α-	linolenic	acid	[ALA],	
eicosapentaenoic	acid	 [EPA]	and	docosahexaenoic	acid	 [DHA]),	and	
results were presented as mg/mL to indicate physiologic quantities.
2.6 | Covariates
Our models adjusted for variables known to impact immune re-
sponse as covariates in the regression models: child sex,44 maternal 
age,45 maternal smoking status,46 maternal BMI47 and gestational 
age.48 Child sex was recorded at birth. Mothers reported their age 
and smoking status at enrolment to the study using questionnaires 
administered	by	trained	nurses.	When	infants	were	~20	months	of	
age, maternal height and weight were recorded, from which their 
postnatal	BMI	was	calculated	(BMI	=	weight	(kg)/height	(m)2). Data 
on prepregnancy BMI were unavailable, and we adjusted for post-
natal BMI as data from our NC1 showed it to strongly correlate 
(r	=	0.93)	with	maternal	BMI	prepregnancy.	Gestational	age	(weeks)	
at blood collection was calculated using the gestational age at deliv-
ery and date of blood collection.
2.7 | Statistical analysis
From	our	final	database	of	mothers	(n	=	1473)	with	complete	inflam-
matory marker data, we removed two mothers with extremely high 
concentrations of multiple inflammatory markers indicating possible 
illness and two additional mothers with a gestational age at blood 
collection (18 and 40 weeks) very far from the average of 28 weeks. 
Undetectable inflammatory marker data are common in multiplex 
assays; however, the MSD platform is extremely sensitive, and as 
such,	≥80%	of	concentrations	were	above	the	LLOD	for	most	mark-
ers.	For	undetectable	values,	we	inputted	LLOD/√2	values	as	a	re-
placement value.49 The lowest rates of detection were observed for 
IL-	2	and	IL-	4	where	only	36%	of	all	samples	were	above	the	LLOD.	
Excluding these markers from Th1, Th2 and Th1:Th2 variables did 
not affect the strength or significance of the modelled relationships 
with	PUFA	or	MeHg.	Therefore,	we	included	these	markers	both	as	
individual variables and within the Th1 and Th2 summed variables.
We	fit	a	series	of	linear	regression	models	to	determine	the	as-
sociation of immune markers with MeHg exposure in pregnancy, and 
the	potential	influence	of	PUFA	on	this	relationship.	Model	assump-
tions, including linearity, constant variance, normality of residuals 
and presence of outlying influential observations, were checked 
graphically using standard methods.50 To better satisfy regression 
assumptions, we used the natural logarithmic transformation of all 
inflammatory markers in the models. Because of the presence of 
zeros in some markers, we added a constant of +1 to each individ-
ual inflammatory marker data, and to the total Th1 and Th2 prior to 
the	natural	log	transformation.	After	excluding	subjects	with	missing	
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values	 for	 model	 covariates	 (including	 119	missing	MeHg	 and	 50	
missing	PUFA),	a	 total	of	n	=	1158	mothers	had	complete	data	 for	
inclusion	in	the	final	regression	models	with	n	=	1156	for	models	ex-
amining	CRP	owing	to	two	additional	subjects	having	no	CRP	data.	
All	 results	presented	are	based	on	n	=	1158	 (or	n	=	1156	for	CRP).	
For each outcome, we fit four models, where each model adjusted 
for gestational age at blood collection, maternal age, smoking status, 
maternal BMI and child sex. The four models additionally adjusted 
for	the	following:	(Model	1)	MeHg;	(Model	2)	MeHg,	n-	3	PUFA	and	
n-	6	PUFA;	(Model	3)	MeHg	and	the	n-	6:n-	3	PUFA	ratio;	and	(Model	
4,	 interaction	model)	MeHg,	 tertiles	 of	 the	 n-	6:n-	3	 ratio	 (low/me-
dium/high), and the interactions of MeHg and n6:n3 ratio tertiles as 
previously reported.33
3  | RESULTS
Table 1 displays the demographic characteristics of the mothers. The 
mean (SD) age of the cohort was 27.17 ± 6.27 years, and the mean 
(SD)	 gestational	 age	 of	 blood	 collection	 was	 27.89	±	1.14	weeks.	
Mean	 (SD)	 whole-	blood	 MeHg	 was	 18.14	±	10.97	μg/L, and the 
PUFA	 n-	6:n-	3	 ratio	 was	 4.34	±	1.61.	 Concentrations	 of	 inflamma-
tory markers (untransformed) and their detection rates are outlined 
in Table 2. The average (SD) Th1:Th2 cytokine ratio was observed to 
be	7.88	±	10.75.
3.1 | MeHg and Th1:Th2, total Th1 and total Th2
Covariate-	adjusted	 associations	 between	maternal	 blood	MeHg,	
PUFA	 and	 the	 inflammatory	 markers	 (presented	 as	 exponenti-
ated slopes, representing multiplicative associations) from fitting 
Models	1-	3	are	presented	 in	Table	3.	Maternal	blood	MeHg	was	
associated with a statistically significant decrease in the Th1:Th2 
ratio	 for	 all	 three	 main-	effects	 models.	 Each	 1	μg/L increase in 
maternal blood MeHg was associated with a decrease in Th1:Th2 
from	 100%	 to	 99.5%	 (P	<	0.003),	 for	 example,	 a	 0.5%	 decrease,	
with	or	without	adjustment	for	PUFA.	Maternal	blood	MeHg	was	
associated	with	 a	 significant	 decrease	 in	 Th1	 for	 all	 three	main-	
effects	 models.	 In	 covariate-	adjusted	 models,	 each	 1	μg/L in-
crease in maternal blood Hg was associated with a 0.7% decrease 
in Th1 (P <	0.001);	with	 or	without	 adjustment	 for	 PUFA.	 There	
were no significant associations between maternal blood MeHg, 
n-	3	PUFA	and	Th2	in	any	of	the	models	after	adjusting	for	covari-
ates.	N-	6	PUFA	was	associated	with	a	significant	17.9%	 increase	
in Th2 (P =	0.013).
In the interaction model, the association between MeHg and 
Th1:Th2	 differed	 by	 n-	6:n-	3	 tertiles	 (P	=	0.02,	 2-	df	 test;	 Figure	1).	
MeHg	was	associated	with	a	decrease	in	Th1:Th2	in	all	n-	6:n-	3	ter-
tiles, but the association was only significantly different from zero 
in	 the	 highest	 n-	6:n-	3	 tertile.	 For	 those	with	 a	 high	 n-	6:n-	3	 ratio,	
each 1 μg/L increase in maternal blood MeHg was associated with a 
decrease of 1.2% in Th1:Th2 (P =	0.005).	The	interactions	between	
MeHg	and	tertiles	of	the	n-	6:n-	3	ratio	were	not	significant	for	total	
Th1 nor total Th2.
TABLE  1 Maternal	characteristics	including	MeHg	and	PUFA	
concentrations	(n	=	1158)
N (%) Mean (SD)
25th, 75th 
percentile
Blood gestational age 
(wk)
27.89	(1.14) 27.43, 28.43
Maternal age (y) 27.17 (6.27) 22.19,	31.48
Smoking (Y) 10 (1)
Maternal BMI (kg/m2) 26.99	(6.55) 21.83, 31.04
Child sex (F) 548	(47)
Blood MeHg (ppb) 18.14	(10.97) 10.70, 22.67
Serum	n-	3	PUFA	
(mg/mL)
0.27	(0.09) 0.20, 0.33
Serum	n-	6	PUFA	
(mg/mL)
1.10	(0.29) 0.89,	1.29
n-	6:n-	3	PUFA  4.34 (1.61) 3.25,	4.98
BMI, body mass index; F, female; MeHg, methylmercury
TABLE  2 Maternal serum inflammatory marker concentrations 
(n	=	1158)
Mean (SD)
25th, 75th 
percentile
% 
Detected 
(>LLOD) LLOD
Th1
IL-	1β 0.32 (0.62) 0.03,	0.39 82.6 0.04
IL-	2 0.29	(0.60) 0.06, 0.32 36.1 0.09
IFN-	γ 5.63	(20.26) 1.03,	4.91 84.4 0.2
TNF-	α 7.26	(7.55) 3.64,	8.89 100 0.04
Th2
IL-	4 0.15	(0.58) 0.01, 0.06 35.5 0.02
IL-	5 1.36 (2.22) 0.40,	1.50 100 0.22
IL-	10 1.59	(7.85) 0.27, 1.70 90.6 0.03
Additional	markers
IL-	6 0.96	(1.44) 0.23, 1.12 88.7 0.06
MCP-	1 76.06	(94.02) 43.63, 87.46 100 0.09
TARC 99.39	(124.16) 47.56,	121.88 100 0.22
sFlt-	1 2160.19	(1786.59) 1221.93,	
2589.82
100 0.56
VEGF-D 743.88	(374.52) 492.37,	
913.98
100 2.53
CRP 3.52	(2.70) 1.38, 4.84 98.9 1
Th1 13.50	(22.56) 5.80,	14.83
Th2 3.10 (8.23) 1.12, 3.36
Th1:Th2 7.88	(10.75) 3.01, 8.47   
Data are untransformed. LLOD: lower limit of detection. Units are pg/mL 
except	for	CRP:	mg/L
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TABLE  3 Main-	effects	models	reporting	covariate-	adjusted	associations	between	MeHg,	PUFA	and	the	markers	of	inflammationa,b
Inflammatory marker MeHg MeHg, n- 3 PUFA and n- 6 PUFA
MeHg and 
n- 6:n- 3 PUFA
Th1/Th2
MeHg 0.995 (0.003) 0.995 (0.004) 0.995 (0.003)
n-	3	PUFA 1.354	(0.210)
n-	6	PUFA 1.099	(0.194)
n-	6/n-	3   0.990	(0.417)
Total Th1
MeHg 0.993 (<0.001) 0.993 (<0.001) 0.993 (<0.001)
n-	3	PUFA 1.439	(0.137)
n-	6	PUFA 1.295 (<0.001)
n-	6/n-	3 1.004 (0.737)
IFN-	γ
MeHg 0.997	(0.258) 0.997	(0.214) 0.997	(0.27)
n-	3	PUFA 2.089 (0.020)
n-	6	PUFA 1.196	(0.060)
n-	6/n-	3 0.994	(0.71)
IL-	1β
MeHg 0.998 (0.002) 0.998 (0.007) 0.998 (0.006)
n-	3	PUFA 0.843 (0.070)
n-	6	PUFA 1.105 (<0.001)
n-	6/n-	3 1.015 (0.001)
IL-	2
MeHg 0.998 (0.015) 0.998 (0.031) 0.998 (0.031)
n-	3	PUFA 0.9023	(0.312)
n-	6	PUFA 1.105 (0.001)
n-	6/n-	3 1.013 (0.010)
TNF-	α
MeHg 0.992 (<0.001) 0.993 (<0.001) 0.993 (<0.001)
n-	3	PUFA 0.938	(0.757)
n-	6	PUFA 1.28 (<0.001)
n-	6/n-	3   1.012 (0.231)
Total Th2
MeHg 0.998	(0.164) 0.998	(0.197) 0.998	(0.216)
n-	3	PUFA 1.063 (0.781)
n-	6	PUFA 1.179 (0.013)
n-	6/n-	3 1.014 (0.206)
IL-	4
MeHg 0.999 (0.041) 0.999	(0.095) 0.999	(0.088)
n-	3	PUFA 0.823 (0.019)
n-	6	PUFA 1.066 (0.011)
n-	6/n-	3 1.014 (0.001)
IL-	5
MeHg 1.001 (0.437) 1.001	(0.533) 1.001	(0.456)
n-	3	PUFA 1.273	(0.192)
n-	6	PUFA 1.043 (0.446)
(Continues)
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3.2 | MeHg and individual inflammatory markers
As	outlined	in	Table	3,	maternal	blood	MeHg	was	significantly	asso-
ciated	with	lower	concentrations	of	IL-	1β,	IL-	2,	TNF-	α,	IL-	10	and	CRP	
with	 or	without	 adjustment	 for	 PUFA.	Maternal	 blood	MeHg	was	
significantly	associated	with	lower	concentrations	in	IL-	4	only	in	the	
model	not	adjusted	for	PUFA.	Maternal	blood	MeHg	was	positively	
associated	with	TARC	and	VEGF-D.
The	n-	3	PUFA	was	associated	with	a	significant	increase	in	IFN-	γ 
and	a	significant	decrease	in	IL-	4	and	CRP.	The	n-	6	PUFA	was	asso-
ciated	with	a	significant	increase	in	total	Th1,	total	Th2,	IL-	1β,	 IL-	2,	
TNF-	α,	 IL-	4,	 IL-	10,	 IL-	6	 and	CRP.	The	n-	6:n-	3	 ratio	was	 associated	
Inflammatory marker MeHg MeHg, n- 3 PUFA and n- 6 PUFA
MeHg and 
n- 6:n- 3 PUFA
n-	6/n-	3 1.001	(0.904)
IL-	10
MeHg 0.996 (0.005) 0.996 (0.010) 0.996 (0.009)
n-	3	PUFA 0.939	(0.752)
n-	6	PUFA 1.179 (0.006)
n-	6/n-	3   1.013 (0.183)
IL-	6
MeHg 0.998	(0.097) 0.998	(0.183) 0.998	(0.167)
n-	3	PUFA 0.88 (0.442)
n-	6	PUFA 1.14 (0.009)
n-	6/n-	3 1.012	(0.157)
MCP-	1
MeHg 1.003	(0.191) 1.003 (0.183) 1.003 (0.178)
n-	3	PUFA 1.275	(0.483)
n-	6	PUFA 1.175	(0.122)
n-	6/n-	3 1.000	(0.995)
TARC
MeHg 1.008 (0.004) 1.009 (0.003) 1.009 (0.003)
n-	3	PUFA 0.833	(0.635)
n-	6	PUFA 1.019	(0.874)
n-	6/n-	3 1.015	(0.445)
sFlt-	1
MeHg 1.000 (0.743) 0.999	(0.732) 0.999	(0.742)
n-	3	PUFA 1.209	(0.359)
n-	6	PUFA 1.021	(0.739)
n-	6/n-	3 0.993	(0.473)
VEGF-D
MeHg 1.004 (0.002) 1.004 (0.001) 1.004 (0.001)
n-	3	PUFA 0.890	(0.510)
n-	6	PUFA 1.091	(0.100)
n-	6/n-	3 1.017	(0.052)
CRP
MeHg 0.996 (0.006) 0.997 (0.028) 0.996 (0.017)
n-	3	PUFA 0.449 (<0.001)
n-	6	PUFA 1.136 (0.044)
n-	6/n-	3 1.034 (0.001)
Values	shown	are	exponentiated	slopes,	representing	multiplicative	associations	(P-	values;	significant	associations	in	bold).
aMain-	effects	models	also	adjusted	for	the	following:	(Model	1)	MeHg;	(Model	2)	MeHg,	n-	3	PUFA	and	n-	6	PUFA;	and	(Model	3)	MeHg	and	n-	6:n-	3	
PUFA.	
bAll	models	adjusted	for	gestational	age	at	blood	collection,	maternal	age,	smoking	status,	maternal	BMI	and	child	sex.	
TABLE  3  (Continued)
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with	a	significant	 increase	 in	 IL-	1β,	 IL-	2,	 IL-	4	and	CRP.	The	 interac-
tions	between	MeHg	and	the	tertiles	of	the	n-	6:n-	3	ratio	were	not	
significant for any of these additional markers.
3.3 | Covariates
Maternal BMI was a significant predictor of many inflammatory 
markers.	After	adjusting	for	other	model	covariates,	BMI	had	a	posi-
tive	association	with	IL-	1β,	TNF-	α,	CRP	and	IL-	6,	and	a	negative	as-
sociation	with	sFlt-	1	and	VEGF-D.	Maternal	age	was	also	a	significant	
predictor	of	several	inflammatory	markers.	After	adjusting	for	covar-
iates,	maternal	age	had	a	positive	association	with	CRP	and	VEGF-D,	
and	a	negative	association	with	sFlt-	1	(results	not	shown).
4  | DISCUSSION
This is one of the first studies to examine associations between ma-
ternal MeHg exposure and immune responses in pregnancy, in a large 
human	 population,	 and	 accounting	 for	 PUFA	 status.	 At	 28	weeks’	
gestation, we observed that increasing maternal MeHg levels were 
associated with a small magnitude decrease in the Th1:Th2 ratio 
along with a decrease in individual and total Th1 cytokines. There 
was no association between MeHg and total Th2 cytokines. Our 
data also suggest an interaction between MeHg exposure and 
the	balance	of	n-	6	to	n-	3	PUFA	status	in	relation	to	these	immune	
marker associations, with MeHg being associated with a decrease in 
Th1:Th2	but	only	at	higher	n-	6:n-	3	PUFA	ratios.	This	association	was	
not	apparent	with	the	lower	ratios	of	n-	6:n-	3;	therefore,	it	is	plausi-
ble	that	the	n-	6	PUFA	are	having	stimulatory	actions	on	Th1	while	a	
higher	concentration	of	n-	3	PUFA	may	be	important	to	mitigate	this	
association.
An	 appropriate	 balance	 between	maternal	 Th1	 and	 Th2	 cyto-
kines is believed to be important for the continuous normal devel-
opment of pregnancy and for optimal foetal outcomes. In this study, 
we observed an immunosuppressive association of MeHg exposure 
at	28	weeks’	gestation	with	the	Th1	cytokines	IL-	1β,	IL-	2	and	TNF-	α. 
This association, which was small in magnitude, was not modified 
by	PUFA	status.	A	recent	meta-	analysis	identified	an	association	of	
anti-	TNF-	α therapies with an increased risk of preterm birth, spon-
taneous abortion and low birthweight.51	Any	 increase	 in	TNF-	α is 
normally	balanced	with	simultaneous	synthesis	of	IL-	10,	which	reg-
ulates	 inflammation.	 The	 balance	 of	 TNF-	α	 and	 IL-	10	 is	 proposed	
to	be	critical	 for	pregnancy	outcome	with	an	 increase	 in	 the	TNF-	
α:IL-	10	ratio	related	to	early	and	late	pregnancy	complications.52	We	
found	MeHg	was	negatively	associated	with	both	TNF-	α	and	IL-	10	
in this cohort, and this may affect this ratio and warrants further 
investigation.	 IL-	1β is involved in implantation and preimplantation 
embryo development53	 with	 elevated	 first	 trimester	 IL-	1β associ-
ated with preterm preeclampsia.54	 Contrary	 to	 our	 findings,	 IL-	1β 
and	TNF-	α were previously shown to be positively associated with 
MeHg	in	a	mother-	child	cohort20 albeit measurements were taken at 
delivery, a time in pregnancy when proinflammatory markers would 
be	increased	by	labour.	IL-	2	functions	in	immune	regulation	by	acti-
vating T cells specifically memory and regulatory T cells and plays 
a role in immune tolerance.55 In particular, during pregnancy a low 
T regulatory (Treg) cell frequency is modulated by changes in cyto-
kine patterns and is associated with adverse pregnancy outcome.56 
Taken	together,	the	associations	we	found	between	MeHg	and	IL-	2,	
TNF-	α	and	IL-	10	warrant	further	investigation	to	determine	whether	
MeHg is suppressing immune regulatory cytokines and to determine 
whether the association, which is small in magnitude, has any clinical 
relevance.
A	 lower	 Th1:Th2	 immune	 response	 in	 the	 second	 trimester	
compared to the first trimester is supportive for physiologic preg-
nancy.57,58 The Th1:Th2 ratio observed in this study is in line with 
what others have reported in pregnancy,57 and considering this co-
hort consisted of only healthy term pregnancies, this is to be ex-
pected. It would also suggest that the association of MeHg with 
the Th1:Th2 is negligible. Nevertheless, in this cohort, the Th1:Th2 
ratio during pregnancy was associated with exposure to MeHg; the 
ratio decreased as the MeHg exposure increased. The clinical rele-
vance of this relationship is difficult to ascertain since the normal 
variations in immune markers during pregnancy are still being de-
termined. In the second and early part of the third trimester of a 
normal pregnancy, the production of the proinflammatory Th1 cy-
tokines	IL-	2,	TNF-	α	and	INF-	γ is normally suppressed, whereas the 
production	of	Th2	regulatory	cytokines	IL-	4	and	IL-	10	is	enhanced,	
supporting	 central	 immune	 tolerance	 at	 the	materno-	foetal	 inter-
face.59 This change is considered important for a healthy term preg-
nancy.9,10	Although	we	did	not	see	any	overall	association	with	Th2,	
F IGURE  1  Interaction models for maternal blood MeHg 
exposure	against	Th1:Th2	cytokine	ratio	at	28	weeks’	gestation.	
Models shown are adjusted for maternal gestational age at blood 
collection, maternal age, smoking status, maternal BMI and child 
sex
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we	did	observe	lower	concentrations	of	IL-	4	and	IL-	10	with	increas-
ing	concentrations	of	MeHg	at	28	weeks’	gestation.	 In	pregnancy,	
IL-	10	is	an	important	immunoregulatory	cytokine	produced	by	cy-
totrophoblasts	 at	 the	materno-	foetal	 interface	 acting	 to	maintain	
the balance between humoral and inflammatory responses.60 Low 
concentrations	 of	 IL-	10	 in	 the	 second	 trimester	 have	 been	 linked	
to recurrent spontaneous abortion.61 Similarly, low concentrations 
of	IL-	4	and	IL-	10	have	been	observed	 in	the	decidua	from	women	
suffering from unexplained recurrent abortions and where spon-
taneous abortion has occurred during the first trimester of preg-
nancy.62 Data on the association of Hg, in particular MeHg, with 
IL-	10	are	limited	and	more	research	is	required	to	ascertain	any	im-
munomodulatory	effects	of	MeHg	on	IL-	10	and	IL-	4	at	critical	peri-
ods of development during pregnancy.
In	 this	 high	 fish-	eating	 cohort,	 adjustment	 for	 PUFA	 did	 not	
alter the associations between MeHg and the inflammatory mark-
ers	with	the	exception	of	IL-	4,	which	was	no	longer	significant	after	
controlling	 for	 PUFA	 status.	 We	 observed,	 however,	 associations	
between	both	n-	3	and	n-	6	PUFA	with	a	number	of	the	quantified	im-
mune	markers,	which	suggest	that	PUFA	is	directly	associated	with	
the	immune	response	at	this	stage	of	pregnancy.	We	observed	that	
n-	6	PUFA	appeared	to	enhance	both	the	Th1	and	the	Th2	response	
and	a	higher	n-	6:n-	3	ratio	was	observed	to	be	associated	with	higher	
concentrations	of	IL-	1β,	IL-	2,	IL-	4	and	CRP,	supporting	a	more	proin-
flammatory	 response.	 In	contrast,	n-	3	PUFA,	as	expected,	was	as-
sociated	 with	 lower	 concentrations	 of	 IL-	4	 and	 CRP	 suggesting	 a	
regulatory	role	of	n-	3	PUFA	at	this	stage	of	pregnancy.	This	finding	
confirms previous results from our cohort showing an inverse rela-
tionship	between	n-	3	PUFA	and	the	proinflammatory	marker	CRP63 
and	supports	the	anti-inflammatory	role	of	n-	3	PUFA	that	is	widely	
reported.64
There	may	be	 an	optimal	 balance	of	 n-	6:n-	3	PUFA	 for	 IL-	4,	 as	
suggested	by	our	finding	that	n-	6	PUFA	was	associated	with	higher	
and	n-	3	PUFA	associated	with	lower	concentrations	of	this	cytokine.	
IL-	4	is	detectable	at	the	maternal-	foetal	interface	throughout	preg-
nancy having a role in placental formation, modulation of tropho-
blast invasion and differentiation, inducing placental angiogenesis 
and inhibiting proinflammatory cytokines. Furthermore, an interac-
tion	between	MeHg	exposure	and	the	balance	of	n-	6	to	n-	3	PUFA	
status in relation to the immune response was apparent, with MeHg 
being	associated	with	a	decrease	 in	Th1:Th2	but	only	at	higher	n-	
6:n-	3	PUFA	ratios.	Given	that	the	association	was	not	significant	at	
lower	ratios	of	n-	6:n-	3	PUFA,	it	may	be	that	the	n-	3	PUFA	are	having	
a regulatory effect on the MeHg immunosuppression of Th1 cyto-
kines.	Achieving	an	optimal	balance	between	n-	6:n-	3	PUFA	during	
pregnancy in controlling inflammatory responses via cytokine signal-
ling may therefore be important for a successful pregnancy. Given 
the	opposing	associations	of	MeHg	and	n-	6	PUFA	on	Th1	markers,	it	
may	be	plausible	that	n-	6	PUFA	also	play	an	important	role	in	stimu-
lating immune responses during pregnancy.
The	n-	3	PUFA	were	associated	with	higher	concentrations	of	IFN-	
γ, a cytokine important in innate immunity and in pregnancy where 
in the first trimester it enhances blood flow to the implantation site 
and aids placental development. MeHg in this study was not as-
sociated	with	 IFN-	γ	or	 IL-	6	which	 is	 contrary	 to	what	others	have	
previously reported.65	As	pregnancy	progresses,	concentrations	of	
IFN-	γ have been shown to decline reflecting Th1 cell–mediated im-
munity suppression.66	The	association	between	n-	3	PUFA	and	IFN-	γ 
observed in this study is similar to that reported elsewhere.67,68 The 
prostaglandin	E2	(PGE2)	decreases	the	production	IFN-	γ; therefore, 
increasing	n-	3	PUFA	concentrations	will	decrease	the	PGE2	result-
ing	 in	higher	 IFN-	γ concentrations.68	 IFN-	γ is important in the re-
sponse to and clearance of viral infection upregulating transcription 
of genes involved in cell cycle regulation, apoptosis and antigen pro-
cessing/presentation;	therefore,	n-	3	PUFA	may	be	having	a	regula-
tory	influence	via	IFN-	γ.
To investigate in greater depth the potential immunomodula-
tory mechanisms of MeHg and potential regulation of inflammation 
by	PUFA,	we	characterized	additional	chemokines	and	angiogene-
sis	markers	within	 this	cohort.	We	measured	TARC,	a	chemokine	
important	in	Th2-	cell	recruitment	in	pregnancy.	The	positive	asso-
ciation	observed	between	maternal	MeHg	and	TARC	is	interesting	
given that we did not see a similar positive association between 
MeHg and Th2 cytokines. One possible explanation for this is that 
elevated	concentrations	of	TARC	in	the	maternal	circulation	act	to	
recruit	Th2	cells	predominantly	at	the	materno-	foetal	 interface.69 
Furthermore,	most	evidence	suggests	that	TARC	plays	a	role	in	the	
accumulation of Th2 cells in the decidua and uterus in early preg-
nancy.69 However, given that a Th2 immune response is reported to 
be advantageous throughout the second and early third trimester 
for successful pregnancy and for foetal growth, the positive associ-
ation	between	MeHg	and	TARC	at	28	weeks’	gestation	may	be	seen	
to be beneficial and warrants further investigation. MeHg exposure 
was	 also	 positively	 associated	with	 concentrations	 of	 VEGF-	D,	 a	
signalling protein which promotes angiogenesis. Serum concentra-
tions	of	VEGF	have	been	found	to	be	higher	during	early	pregnancy	
than in nonpregnancy,70 reflecting the increase in maternal blood 
volume	 and	development	 of	 the	 utero-	placental	 circulation.71	 An	
imbalance in angiogenesis markers has been implicated in pre-
eclampsia,72	although	no	differences	in	VEGF-	D	have	been	found	
between preeclamptic and normotensive pregnant women.73 
Treatment of mast cells with inorganic HgCl2 was shown to stimu-
late	VEGF-	D	and	IL-	6	release,	which	could	in	turn	promote	inflam-
mation	 at	 the	 blood-	brain	 barrier.19 Further research is required 
to examine whether the positive association between MeHg and 
VEGF-	D	at	28	weeks’	gestation	could	have	implications	for	foetal	
development	through	potential	effects	on	the	maternal-	foetal	cir-
culation. In contrast to the Th1 and Th2 cytokines, we observed no 
associations	 between	 PUFA	 status	 and	 any	 chemokine	 or	 angio-
genesis marker.
This study has several strengths. This large cohort had high fish 
consumption,	with	concurrent	high	intake	of	n-	3	PUFA	and	relatively	
high	MeHg	exposure	(10	times	higher	than	in	the	USA);74 therefore, 
any possible associations with these factors should have been de-
tected in this study. Robust physiologic measures of both MeHg ex-
posure	and	PUFA	status	were	used,	and	the	cohort	size	permitted	
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investigation of interactions between maternal MeHg exposure and 
PUFA	status.	The	study	also	has	a	number	of	limitations.	We	did	not	
speciate Hg, and although we believe that within the Seychelles pop-
ulation, some 80% of blood THg is MeHg, this ratio may differ in 
other populations with different exposures and may also be altered 
during gestation.75 The study included only normal pregnancies and 
all	maternal	blood	samples	were	taken	at	28	weeks’	gestation,	so	we	
could	not	examine	MeHg	and	PUFA	exposure	across	all	trimesters.	
When	 comparing	 associations	 between	 MeHg	 and	 inflammatory	
markers there is an inherent unreliability in their categorization as 
pro-	and	anti-inflammatory	which	challenges	their	interpretation.76 
Inflammatory marker concentrations may also be impacted by time 
of day, acute stress, possibility of infection, fitness level, and feeding 
state of the participants, as well as the length of storage time of the 
blood samples.77	The	pro-	and	anti-inflammatory	responses	of	a	par-
ticular marker may also vary under different activating signals, cell 
targets, oxidative stress and temporal conditions. The inclusion of ex 
vivo functional analyses of immune response would have enhanced 
the understanding and impact of these results. Restrictions, how-
ever, in study design and laboratory capabilities prevented this type 
of	analysis	 in	the	field.	Additionally,	the	study	was	cross-	sectional.	
These and other factors make us cautious in interpreting the data.
5  | CONCLUSIONS
In this exploratory study, we found associations of maternal MeHg 
with	markers	of	maternal	 immune	function	at	28	weeks’	gestation.	
Additionally,	the	n-	3	and	n-	6	PUFA	were	found	to	have	associations,	
which might indicate suppressive and stimulatory immune responses, 
respectively.	The	associations	with	PUFA	were	largely	independent	
of	MeHg,	albeit	a	significant	interaction	between	MeHg	and	the	n-	
6:n-	3	ratio	on	the	Th1:Th2	ratio	suggests	that	the	n-	3	PUFA	could	
potentially mitigate the immunosuppressive associations of MeHg 
observed. Overall, the associations were of small magnitude and 
of unclear significance given normal immune changes during preg-
nancy. Further research on these associations is indicated.
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